Is Fabre-Kramer’s Gepirone Antidepressant Rising From The Dead After 8 Years?
This article was originally published in The Pink Sheet Daily
Executive Summary
Nothing has been heard about the major depressive disorder treatment since FDA issued a third “not approvable” letter in 2007; advisory committee to discuss NDA in December.
You may also be interested in...
Do Negative Trials Count More Than Successful Ones?
Fabre-Kramer, FDA dispute over efficacy of the antidepressant gepirone heads to Psychopharmacologic Drugs Advisory Committee.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.